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Unwell in hospital but not incapable: cross-
sectional study on the dissociation of decision-
making capacity for treatment and research in
in-patients with schizophrenia and
related psychoses
Benjamin Walter Jack Spencer, Tania Gergel, Matthew Hotopf and Gareth S. Owen
Background
Consent to research with decision-making capacity for research
(DMC-R) is normally a requirement for study participation.
Although the symptoms of schizophrenia and related psychoses
are known to affect decision-making capacity for treatment
(DMC-T), we know little about their effect on DMC-R.
Aims
We aimed to determine if DMC-R differs from DMC-T in propor-
tion and associated symptoms in an in-patient sample of people
with schizophrenia and related psychoses.
Method
Cross-sectional study of psychiatric in-patients admitted for
assessment and/or treatment of schizophrenia and related
psychoses. We measured DMC-R and DMC-T using ‘expert
judgement’ clinical assessment guided by the MacArthur
Competence Assessment Tool for Clinical Research, the
MacArthur Competence Assessment Tool for Treatment and the
legal framework of the Mental Capacity Act (2005), in addition to
symptoms of psychosis.
Results
There were 84 participants in the study. Half the participants had
DMC-R (51%, 95%CI 40–62%) and a third had DMC-T (31%, 95%CI
21–43%) and this differencewas statistically significant (P < 0.01).
Thought disorder wasmost associatedwith lacking DMC-R (odds
ratio 5.72, 95% CI 2.01–16.31, P = 0.001), whereas lack of insight
was most associated with lacking DMC-T (odds ratio 26.34,
95% CI 3.60–192.66, P = 0.001). With the exception of improved
education status and better DMC-R, there was no effect of
sociodemographic variables on either DMC-R or DMC-T.
Conclusions
We have shown that even when severely unwell, people with
schizophrenia and related psychoses in in-patient settings
commonly retain DMC-R despite lacking DMC-T. Furthermore,
different symptoms have different effects on decision-making
abilities for different decisions. We should not view in-patient
psychiatric settings as a research ‘no-go area’ and, where
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Decision-making capacity (DMC) can be framed as the ability to
make a decision that has legal authority when consent is formalised,
such as decisions around medical treatment or research. DMC is
defined as being specific to the decision in question: different
factors will affect the ability to make different decisions, and the
presence or absence of DMC for one type of decision does not neces-
sarily imply the status of DMC for other decisions. DMC is a legal
concept and the final arbiter or ‘gold standard’ is a decision by
the court. However, it is psychopathological symptoms that lead
to impairment of DMC and, when finding that DMC is lacking in
an individual, these symptoms must be observed to have an
impact on DMC. Thus, DMC is a legal construct underpinned by
psychopathology.
Schizophrenia and related psychoses (such as schizoaffective
disorder, delusional disorder, and acute and transient psychoses)
are commonly associated with impairments in DMC.1 This may
influence the decisions of institutional review boards or research
ethics committees when it comes to recruiting research participants
with these conditions. However, there is an indisputable need for
more research in schizophrenia and related psychoses,2 especially
with participants who are detained in hospital, severely unwell, or
with chronic illness and prominent negative symptoms – people
for whom there is evidence of systemic exclusion from research
studies.3,4
Participation in human research either requires the consent of
participants (with DMC for research, DMC-R), or that of the
legally authorised representative in those lacking DMC-R.5 If an
individual objects to participation, irrespective of their DMC-R,
the objection is always respected.5 However, the psychopathology
of schizophrenia and related psychoses can have a substantial
impact on both DMC for treatment (DMC-T) and DMC-R (for a
review see Spencer et al, 20171). There is a moral imperative to
adequately protect people from the consequences of a decision
made when DMC is lacking, but also to ensure autonomy is
respected and that DMC is maximised. Therefore, to recruit
people with schizophrenia and related psychoses to research
studies safely, we need to understand the nature of DMC-R when
people are acutely unwell.
Standards of assessing DMC
DMC can be measured as either a binary categorical outcome or on
dimensional measures of key abilities. Both the categorical outcome
and abilities are defined legally and differ by jurisdiction; although
the definitions in the USA and England and Wales are largely
viewed to be synonymous.6 In England and Wales, these abilities
are defined in the Mental Capacity Act (2005) (MCA) as ‘under-
standing’, ‘retention’, ‘use and weigh’ and ‘communicating a
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choice’;7 whereas in the USA they are defined as ‘understanding’,
‘appreciation’, ‘reasoning’ and ‘expressing a choice’ (the ‘four
factors’).8 In practice, the routine standard is a clinical or court
assessment of DMC returning a binary judgement. This assessment
may be framed by legal criteria such as the MCA in the UK or the
four-factor model in the USA. We name this standard clinical
‘expert judgement’. Research in the field has predominantly used
only dimensional measures of the four factors to facilitate more
detailed study of the key abilities. We have previously argued that
there are limitations in using these measures alone as they do not
necessarily inform DMC, which is inherently binary. For that, one
needs to include a measure using an expert judgement standard.1
Current evidence
There is evidence that different psychopathology affects different
decisions differently: our systematic review of previous research
has shown that insight has the largest effect on DMC-T, whereas
neurocognitive deficits have the most impact on DMC-R.1
However, no study has ever compared the impact of psychopath-
ology on two different types of decision concomitantly, a necessary
feature to control for differing study designs. Few studies to date
have investigated DMC-R in an in-patient setting with severely
unwell participants, and none of these used an expert judgement
measure. We therefore aimed to investigate the proportion and
associated symptoms of DMC-R in severely unwell in-patients
with schizophrenia and related psychoses compared with DMC-T.
Studies of DMC-R comprise a study assessing DMC-R and a
‘parent study’ (the study that is explained to participants and for
which their DMC is assessed). For our comparison of DMC-R
and DMC-T, we desired a parent study that was clearly separate
from decisions around current treatment to delineate these two
decisions. Therefore, we chose a non-therapeutic research project
– the ‘National Institute for Health Research (NIHR) BioResource
study’ – as we considered that there would be a large overlap




We recruited people admitted to eight wards in South London and
Maudsley National Health Service Foundation Trust. Eligible partici-
pants were approached as soon as possible, from24 h after admission.
We aimed to study schizophrenia and related psychoses to focus
on the core symptoms of ‘schizophreniform’ psychotic illnesses of
interest (delusions, hallucinations, thought disorder, negative
symptoms, neurocognitive symptoms and lack of insight). With
regards to thought disorder, we were particularly interested in
those disturbances in thought found in schizophrenia, such as
‘distorted connections between successive thoughts’9 and ‘loss of
the normal structure of thinking’,10 as assessed by the Positive
and Negative Syndrome Scale (PANSS)11 under item P2 ‘conceptual
disorganization’.
Psychiatric diagnosis is fluid. Decisions regarding inclusion and
exclusion criteria were made to balance the need to best sample the
population with symptoms of schizophreniform psychotic illness,
while also obtaining a homogeneous sample to perform the analysis
between predictor variables and the outcomes of assessment of
DMC-R and DMC-R and to manage possible confounding variables
(severe affective symptoms in affective disorders such as depression,
or underlying neurological illness such as in organic brain disease).
Bipolar affective disorder and related affective psychoses, such as
psychotic depression, were excluded because these disorders have
separate and distinctive putative mechanisms that influence DMC
independently of the symptoms of schizophrenia and related psych-
oses (see for example Owen, 201312 for a discussion on the mechan-
isms of affective symptoms that influence DMC-T in severe
depression). Despite having prominent affective symptoms by def-
inition, we decided to include schizoaffective disorder as it retained
the core symptoms that we wished to investigate. We defined the
criteria for the purposes of admission as ‘admission for assessment
and/or treatment’ of schizophrenia and related psychoses. This was
to exclude those people who were well from a psychosis perspective
but were admitted for other reasons, such as social or housing issues.
The inclusion criteria were as follows: age > 18; fluency in
English; diagnosis of non-affective psychotic illness as defined by
F20–F2913 of the ICD-10 (1992) (excluding F21 ‘schizotypal dis-
order’, which can be considered to be a personality disorder and
has only some of the features of schizophrenia10) or 295, 297 and
298 of the DSM-IV (1994);14 and primary purpose of admission
into hospital must have been for the assessment and/or treatment
of symptoms of psychosis. The exclusion criteria were current
intoxication and previous recruitment into a BioResource study.
Participants were offered £10 as compensation for their time. All
study interviews were performed by the first author. We were able
to recruit participants lacking DMC-R for participation in the
present study by seeking the approval of a nominated consultee.
In England and Wales, the Mental Health Act (1983) can be used
to authorise the detention and treatment of in-patients with
mental disorder based on risk. We did not exclude detained
people from participating and, in fact, 75% of our participants
were formally detained at the time of participation. This study
was approved by the Camberwell and St Giles Ethics Committee
(reference 15/LO/0427).
Measures of DMC
We selected the NIHR BioResource as the ‘parent study’ because it is
a real non-therapeutic research study that recruits in in-patient set-
tings.15 The NIHR BioResource is a biobank study that collects bio-
logical (blood and/or saliva) samples and links them to medical
data. Key issues of the BioResource include re-contacting partici-
pants in the future based on phenotype or genotype, ‘broad
consent’ for future research and that participation will have no
therapeutic benefit to the participant (vis-à-vis the ‘therapeutic mis-
conception’16). In liaison with experts in biobanking and our study’s
Service User and Carer Advisory Group, we distilled the key infor-
mation about BioResource research that an individual would need
to consider to provide valid informed consent. DMC-R was exam-
ined by semi-structured interview, using the legal framework for the
assessment of capacity under the MCA, dichotomised into a binary
outcome.
The interview used the MacArthur Competence Assessment
Tool for Clinical Research (MacCAT-CR).17 The MacCAT-CR is
a semi-structured tool that returns scores on ‘understanding’,
‘appreciation’, ‘reasoning’ and ‘communication’. We adapted the
tool for BioResource research and, using similar methods as
described by Cairns 200518 and Kim 2011,19 were able to show an
excellent inter-rater reliability with a pairwise kappa of 0.8
(corresponding author for details). We measured DMC-T using a
similar approach as for DMC-R. Here, the decision was framed
around ‘admission and treatment’ in hospital (seen conjunctively)
and was informed by relevant information about the participant’s
diagnosis, symptoms, purpose and reasons for admission, and
recommended treatment from the case notes and discussion
with the clinical team. We structured the interview using
the MacArthur Competence Assessment Tool for Treatment
(MacCAT-T),20 which is structured similarly to the MacCAT-CR.
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Other assessments
Basic demographics were collected from participants, clinical diag-
nosis under ICD-1013 was obtained from the assigned diagnosis in
the case notes and validated using theOperational Criteria Checklist.21
Participants underwent assessments using the PANSS11 (this includes
a measure of insight, PANSS item G12), Young’s Mania Rating Scale
(YMRS),22 the 17-itemHamilton Rating Scale for Depression (HRSD-
17),23 Health of the Nation Outcome Scales (HoNOS)24 and the
Clinical Global Impression – Severity Scale (CGI-S).25
We developed a Neurocognitive Assessment Battery for the
study that included: verbal and category fluency,26 Digit Span,27
Digit Symbol Substitution Test,27 Letter-Number Sequencing,27
story memory test28 and Trail Making Test parts A and B.29
These tests were selected for brevity of assessment and to focus on
deficits in verbal and working memory present in those with schizo-
phrenia and related psychoses.30,31
Statistical analysis
All analyses were performed using Stata version 14 (StataCorp,
Texas). Measures of symptoms were converted into z-scores based
on the sample mean and standard distribution to facilitate direct
comparison. Where the distribution of scores was skewed, the
score was trichotomised into high, medium or low, based on the
sample range. Within the neurocognitive measures, the number of
missing items was very high (>70% of cases were missing at least
one item). This was a severely unwell sample and missing data
were commonly due to participant disengagement from further
assessments. We were interested in the core symptoms of psychosis,
such as hallucinations and delusions. Therefore, we did not impute
these missing data and we performed a ‘complete case’ analysis,
selecting the relevant measures from the Neurocognitive
Assessment Battery with the most data (Digit Span for working
memory; Logical Memory 1 for short-term memory). To enable
direct comparison between the PANSS and neurocognitive items,
we restricted the analysis of these items to those cases with data
for all measures (the ‘restricted data set’).
Results
Study sample
A total of 84 participants completed the DMC-R assessments.
Consultee approval to consent of the study was obtained in three
participants, with one subsequently regaining DMC-R for the
present study. Basic sociodemographics and measures on the
symptom scores of the sample are provided in Table 1.
Measures of DMC-R and DMC-T
We found that half of the participants had DMC-R (51%, 95% CI
40–62%), compared with a third who had DMC-T (31%, 95% CI
21–43%). This difference was highly statistically significant:
P < 0.01. Table 2 shows the distribution of people having DMC-R
v. DMC-T. Although in most cases participants either lacked or had
both DMC-R and DMC-T (n = 59, 74%), there were dissociations:
23% (n = 18) had DMC-R but lacked DMC-T, and 4% (n = 3)
lacked DMC-R but had DMC-T.
Associations with DMC-R and DMC-T
Sociodemographics
Associations between sociodemographic variables and DMC-R and
DMC-T are presented in Table 3. There were no associations with
age, gender, ethnicity, previous involvement in research and
current employment with either DMC-R or DMC-T. Highest
educational attainment (A-Level/12th grade or above) was asso-
ciated with having DMC-R (odds ratio 0.31, 95% CI
0.12–0.75, P = 0.010); however there were no associations with
highest educational attainment and DMC-T.
Clinical factors and symptoms
Associations between clinical factors and symptoms and DMC-R
and DMC-T are presented in Table 4. Diagnostic subtype was not
associated with lacking either DMC-R or DMC-T, with the
Table 2 Presence of DMC-R v. DMC-T
DMC-T
Present Absent
DMC-R Present 22 (28%) 18 (23%)
Absent 3 (4%) 37 (46%)
DMC-R, decision-making capacity for research; DMC-T, decision-making capacity for
treatment.
Table 1 Descriptive sociodemographics and symptom scales of
participants
Sociodemographics
Age (n = 84) 38.40 (12.21)
Gender (n = 84)
Number female 21 (25%)
Ethnicity (n = 80)
White British 21 (25%)
Black African 21 (25%)
Black Caribbean 17 (20%)
Mixed 12 (14%)
Other Black and minority ethnic 5 (6%)
White other 4 (5%)
Education (n = 84)
GCSE/10th grade or below 37 (44%)
A-Level/12th grade or above 47 (56%)
Current employment (n = 84)
Employed 11 (13%)
Unemployed 73 (87%)
Previous involvement in research (n = 84)
Other research – prior involvement 38 (45%)
No prior research discussions 46 (55%)
Days from admission to recruitment (n = 84) 11 (17)a
Clinical variables
Primary diagnosis (n = 84)
F20: schizophrenia 61 (73%)
F25: schizoaffective disorder 14 (17%)
F22: persistent delusional disorder 4 (5%)
Other (F23, F28, F29) 5 (5%)




Total score (n = 64) 68.66 (15.33)
Positive symptom score (n = 78) 20.77 (6.47)
Negative symptom score (n = 78) 12 (12)a
General symptom score (n = 69) 33.13 (6.88)
Insight
Item G12 insight (n = 77) 4.44 (1.63)
Global illness severity
CGI (n = 84) 4.08 (0.88)
HoNOS (n = 81) 12.70 (5.89)
Affective symptoms
YMRS (n = 65) 12.06 (7.27)
HRSD-17 (n = 65) 5 (6)a
Neurocognition
Neurocognitive z-score (n = 25) −1.28 (0.98)
Results are presented as means and s.d. unless specified. PANSS, Positive and Negative
Syndrome Scale; CGI, Clinical Global Impression; HoNOS, Health of the Nation Outcome
Scales; YMRS, Young’s Mania Rating Scale; HRSD-17, 17-item Hamilton Rating Scale for
Depression.
a. Median and interquartile range.
Spencer et al
486
exception of delusional disorder, in which all participants had
DMC-R but lacked DMC-T (n = 4). Detention in hospital was
associated with lacking DMC-T (odds ratio 3.41, 95% CI 1.16–9.96,
P = 0.025) but not DMC-R.
Measures of total psychotic symptom burden or overall illness
severity (PANSS total score, CGI and HoNOS) were associated
with worse DMC-R and DMC-T. There were no associations with
HRSD-17 and lacking either DMC-R or DMC-T. Manic symptoms
were associated with lacking both DMC-R and DMC-T with similar
effect sizes (odds ratios 3.00, 3.74).
The restricted data set did not differ significantly from the full
data set on age (mean 39.93 (12.56) v. 38.40 (12.21)), gender
Table 3 Odds ratios of sociodemographic predictor variables on lacking DMC-R and DMC-T
(n DMC-R, n DMC-T) DMC-R DMC-T
Odds ratio 95% CI P Odds ratio 95% CI P
Age (n = 84, 80)
Years 1.03 0.99–1.07 0.116 1.04 0.99–1.08 0.100
Gender (n = 84, 80)
Male 1 1
Female 0.56 0.20–1.54 0.260 0.80 0.27–2.33 0.676
Ethnicity (n = 80, 76)
White British 1 1
Black African 0.56 0.17–1.91 0.356 0.64 0.17–2.38 0.508
Black Caribbean 0.67 0.18–2.41 0.537 0.94 0.23–3.92 0.936
Mixed 0.54 0.13–2.25 0.394 1.14 0.22–5.87 0.873
Other Black and minority ethnic 1.13 0.15–8.21 0.908 1.71 0.16–18.73 0.659
White other 2.25 0.20–25.37 0.512 a
Involvement in research (n = 84, 80)
No prior involvement in research 1 1
Previous involvement in research 1.09 0.46–2.58 0.843 1.14 0.44–2.95 0.786
Education (n = 84, 80)
GCSE/10th grade or below 1 1
A-Level/12th grade or above 0.31 0.12–0.75 0.010 0.63 0.24–1.66 0.348
Current employment (n = 84, 80)
Unemployed 1
Employed 0.86 0.24–3.06 0.811 2.25 0.45–11.28 0.324
Diagnosis (n = 84, 80)
Schizophrenia 1 1
Schizoaffective disorder 0.85 0.27–2.71 0.782 0.61 0.17–2.20 0.454
Delusional disorder b b
Other 0.21 0.02–2.01 0.176 0.66 0.10–4.29 0.662
Detained at time of interview (n = 84, 80)
Informal 1 1
Detained 1.79 0.65–4.91 0.260 3.41 1.16–9.96 0.025
Days until recruited (n = 84)
Days until recruited 1.01 0.99–1.03 0.282 1.00 0.98–1.02 0.832
Significant values have been highlighted in bold type.
DMC-R, decision-making capacity for research; DMC-T, decision-making capacity for treatment.
a. All participants of White other ethnicity lacked DMC-T.
b. All participants with delusional disorder (n = 4) had DMC-R and lacked DMC-T.
Table 4 Odds ratios of symptom predictor variables on lacking DMC-R and DMC-T
(n DMC-R, n DMC-T) DMC-R DMC-T
Odds ratio 95% CI P Odds ratio 95% CI P
Global Severity Assessments
CGI score (n = 84, 80) 6.59 2.93–14.81 <0.001 3.73 1.88–7.40 <0.001
HoNOS (n = 81, 77) 2.50 1.48–4.23 0.001 1.82 1.07–3.09 0.026
Affective symptoms
HRSD-17 T scorea (n = 65, 65) 0.31 0.07–1.35 0.119 0.48 0.16–1.48 0.203
YMRS score (n = 65, 65) 3.00 1.53–5.88 0.001 3.74 1.69–8.31 0.001
Psychosis and neurocognitive symptom measures – restricted data set n = 46
PANSS total symptom 8.99 2.60–31.13 0.001 2.36 1.08–5.15 0.031
PANSS positive symptom 4.00 1.70–9.41 0.002 3.88 1.44–10.42 0.007
PANSS negative symptom T scorea 2.33 0.91–5.98 0.079 0.89 0.36–2.22 0.805
Delusions 2.13 1.09–4.16 0.026 3.67 1.62–8.32 0.002
Thought disorder 5.72 2.01–16.31 0.001 1.82 0.85–3.90 0.125
Hallucinations T scorea 1.41 0.55–3.60 0.473 1.47 0.52–4.13 0.466
Insight 1.86 0.91–3.79 0.089 26.34 3.60–192.66 0.001
Digit Span 1.67 0.76–3.67 0.202 1.94 0.89–4.27 0.098
Logical Memory 1 recall 2.68 1.43–5.02 0.002 1.38 0.81–2.34 0.232
All symptom measures have been converted into z-scores based on the sample mean and s.d. to facilitate direct comparison unless indicated.
Significant values have been highlighted in bold type.
DMC-R, decision-making capacity for research; DMC-T, decision-making capacity for treatment; CGI, Clinical Global Impression; HoNOS, Health of the Nation Outcome Scales; HRSD-17, 17-
item Hamilton Rating Scale for Depression; YMRS, Young’s Mania Rating Scale; PANSS, Positive and Negative Syndrome Scale.
a. T score: trichotomised by sample range into scores of low 1, medium 2 or high 3 due to skewed distribution.
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(female n = 13, 28% v. 21, 25%) and education A-Level/12th grade
and above (n = 30, 65% v. 47, 56%). With the restricted data set,
PANSS positive symptoms were associated with both lacking
DMC-R and DMC-T (odds ratios 4.00, 3.88); although PANSS
negative symptoms were not associated with lacking either DMC-
R or DMC-T, significance was just missed for DMC-R (odds ratio
2.33, 95% CI 0.91–5.98, P = 0.079). In terms of the individual key
symptoms of psychosis, hallucinations were not associated with
lacking either DMC-R or DMC-T, delusions were associated with
lacking both DMC-R and DMC-T (odds ratios 2.13, 3.67) but
thought disorder was only associated with lacking DMC-R (odds
ratio 5.72, 95% CI 2.01–16.31, P = 0.001). Worse Digit Span per-
formance was not associated with lacking either DMC-R or
DMC-T, but worse Logical Memory 1 performance was associated
with lacking DMC-R (odds ratio 2.68, 95% CI 1.43–5.02, P = 0.002).
Lack of insight had the largest effect on lacking DMC-T (odds ratio
26.34, 95% CI 3.60–192.66, P = 0.001), but narrowly missed signifi-
cance with lacking DMC-R (odds ratio 1.86, 95% CI 0.91–3.79, P =
0.089).When the data set was unrestricted, thought disorder was asso-
ciated with lacking DMC-T (odds ratio 2.12, 95% CI 1.22–3.68, P =
0.008) and lack of insight was associated with lacking DMC-R (odds
ratio 2.76, 95% CI 1.55–4.90, P = 0.001).
Discussion
Main findings
We have shown that DMC-R is different from DMC-T in terms of
the proportion of people in which is it present while unwell in hos-
pital and the associated symptoms with lacking DMC. When
unwell, around half of the participants with schizophrenia and
related psychoses had DMC-R, which is more than those with
DMC-T. Symptoms that had the largest effect on DMC-R were
related to disorganised thinking and poor short-term memory
(thought disorder and Logical Memory 1). In contrast, the largest
and most significant effect on DMC-T was lack of insight.
Consistent with other work, we did not find an association with
sociodemographic variables and either DMC-R and DMC-T, with
the exception of an effect of greater years of education and having
DMC-R. Out of the core symptoms of psychosis, hallucinations
and delusions, only delusions had an effect on DMC-R and
DMC-T, whereas hallucinations had no effect. In all measures of
overall psychosis symptom severity used in this study, higher symp-
toms scores were associated with worse DMC-R and DMC-T.
Insight
The finding that insight has a central role in DMC-T is consistent
with previous work.1 The association with DMC-R just missed sig-
nificance in the restricted data set, but was significantly associated in
the unrestricted data set. We deliberately selected a parent study
which we believed would not require insight into one’s own
illness. One explanation for this could be that lack of insight is asso-
ciated with a reduction of meta-cognitive ability32 and thus would
have an impact on decision-making in general. However, it is pos-
sible that there remains a role for insight in decision-making, even
in decisions regarding non-therapeutic research.
Thought disorder and understanding
The participants that lacked DMC-R but had DMC-T bear special
consideration. In two out of three of these participants, the main
reason for lacking DMC-R was a lack of understanding due to
thought disorder. But this was not severe enough to affect under-
standing in DMC-T and participants were protected from the
effects of the thought disorder due to prior knowledge. DMC-R
required the ability to understand and process novel information,
but this was not necessarily the case in DMC-T and this may
explain the strong effect of short-term memory performance and
thought disorder on DMC-R rather than DMC-T. There are
many studies regarding the utility of educational interventions to
support understanding for research participation in schizophrenia
and related psychoses (see for example33,34). Our findings both
support this and the importance of decisional support tools
around understanding in research participation discussions.
Decision and person specificity of DMC-R and DMC-T
Our data strongly support the legal and conceptual premise of deci-
sion specificity. We have found that two different decisions differ in
both the proportion of people having DMC and the associated
symptoms. Of interest is the impact of the cognitive symptoms
such as short-term memory and thought disorder (although a
primary symptom of psychosis thought disorder clearly has a
direct cognitive effect) and their strong impact on DMC-R but
limited impact on DMC-T. One might assume that these would
affect all decisions equally, however we found evidence to the con-
trary. Although it is self-evident that some decisions may require
more detailed understanding than others, the impact of symptoms
on these decisions may be different, especially if there is prior
knowledge of the subject area. Therefore, when interpreting our
results, it is worth reflecting that the impact of symptoms will not
just vary by decision, but also by individual and their previous life
experience and knowledge.
Limitations
Power and missing data
We were powered to detect a large effect size between the symptom
measures and DMC-R and DMC-T, which we deemed to be clinic-
ally relevant. Because this is a severely unwell sample, our study is
inevitably limited by missing data, particularly within the neurocog-
nitive assessment. To compensate for this, we restricted the analysis
of PANSS and neurocognitive items for cases in which we had full
data, so that direct comparisons of symptoms and associations
with DMC-R and DMC-T could be made. This limits the power
of the study. The results do not substantially differ from the unre-
stricted data set analysis other than for those already mentioned
and they enable direct comparison, which is a limitation of the unre-
stricted data set.
Selection bias
Our primary goal was to explore the proportion of DMC-R in the
in-patient population and we designed our study accordingly to
minimise the risk of selection bias. However, bias likely remained:
The level of PANSS negative symptoms was very low in our
sample (total score of 12 out of a minimum and maximum range
of 7–49). This is unsurprising considering the substantial motiv-
ation required to participate in a research study comprising multiple
interviews taking >90 min in total. A high proportion of people in
our study reported previous participation in research. This may
indicate that people who were interested and open to participate
in research in general may also be likely to wish to participate in a
research study. Finally, it was not possible for the research team
to approach many individuals due to risk of violence or sexual dis-
inhibition. We consider these selection biases to be of limited
concern because, with consent to research, we are concerned with
the population that will safely volunteer to participate in research
when severely unwell in hospital; these biases would not have sig-




To our knowledge this is the first study to investigate DMC-R in an
in-patient setting with severely unwell participants, using a categor-
ical outcome of the expert judgement standard. This is also the first
study to directly compare two different DMC decisions for the same
individual as well as their symptom and sociodemographic associa-
tions, thereby exploring the decision specificity of DMC and dem-
onstrating its presence and impact.
We have shown that, even when severely unwell, people
with schizophrenia and related psychoses commonly retain DMC-
R for non-therapeutic research, even when lacking DMC-T.
Furthermore, different symptoms have different effects on deci-
sion-making abilities for different decisions. Therefore, we should
not make assumptions about an individual’s DMC-R based on
their DMC-T, their degree of illness or their symptom profile. To
do so risks the continued exclusion of a patient group that we
know has high rates of DMC-R and for whom research is urgently
needed to improve care. We should not view in-patient psychiatric
settings as a research no-go area and, with suitable safeguards, our
results suggest we should recruit in these settings. Just because
someone is in hospital with schizophrenia or related psychoses
does not mean they are incapable. If we talk to them about research
projects they may want to – and be able to – participate.
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